BDBM277126 4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-7- {[2-(trifluoromethyl)pyridin-4-yl]methyl}- 5,6,7,8-tetrahydro-1,7-naphthyridine-2- carboxamide::US10072003, Example 2-19
SMILES: NC(=O)c1cc(c2CCN(Cc3ccnc(c3)C(F)(F)F)Cc2n1)-n1ccc(n1)C(F)(F)F
InChI Key: InChIKey=QPCJMKQAFCOTSR-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Metabotropic glutamate receptor 2 (Homo sapiens (Human)) | BDBM277126 (4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-7- {[2-(tr...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.16E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA US Patent | Assay Description The utility of the compounds of the invention as antagonists of metabotropic glutamate receptor activity, in particular mGluR2 activity, may be demon... | US Patent US10072003 (2018) BindingDB Entry DOI: 10.7270/Q23R0VXK | |||||||||||
More data for this Ligand-Target Pair |